Patents by Inventor Hans-Falk Rasser
Hans-Falk Rasser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965199Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.Type: GrantFiled: January 31, 2022Date of Patent: April 23, 2024Assignee: SANOFIInventors: Claus Lattemann, Thomas Stillger, Bernd Janocha, Hans-Falk Rasser, Sebastian Rissom, Simone Anderko, Rita Bernhardt, Frank Hannemann
-
Patent number: 11608514Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.Type: GrantFiled: June 26, 2019Date of Patent: March 21, 2023Inventors: Claus Lattemann, Thomas Stillger, Bernd Janocha, Hans-Falk Rasser, Sebastian Rissom, Simone Anderko, Rita Bernhardt, Frank Hannemann
-
Publication number: 20220228189Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.Type: ApplicationFiled: January 31, 2022Publication date: July 21, 2022Inventors: Claus Lattemann, Thomas Stillger, Bernd Janocha, Hans-Falk Rasser, Sebastian Rissom, Simone Anderko, Rita Bernhardt, Frank Hannemann
-
Publication number: 20220136029Abstract: The present invention concerns a genetically modified bacterium and to its industrial application, in particular in the 1,2-dehydrogenation of steroids.Type: ApplicationFiled: February 7, 2020Publication date: May 5, 2022Inventors: Claus Tobias LATTEMANN, Bernd JANOCHA, Hans-Falk RASSER, Sebastian RISSOM
-
Patent number: 10947284Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.Type: GrantFiled: April 24, 2019Date of Patent: March 16, 2021Assignee: Pieris Pharmaceuticals GmbHInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20190382455Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.Type: ApplicationFiled: April 24, 2019Publication date: December 19, 2019Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20190352690Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.Type: ApplicationFiled: June 26, 2019Publication date: November 21, 2019Inventors: Claus Lattemann, Thomas Stillger, Bernd Janocha, Hans-Falk Rasser, Sebastian Rissom, Simone Anderko, Rita Bernhardt, Frank Hannemann
-
Patent number: 10385376Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.Type: GrantFiled: October 29, 2015Date of Patent: August 20, 2019Assignee: SANOFIInventors: Claus Lattemann, Thomas Stillger, Bernd Janocha, Hans-Falk Rasser, Sebastian Rissom, Simone Anderko, Rita Bernhardt, Frank Hannemann
-
Patent number: 10316071Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.Type: GrantFiled: July 6, 2016Date of Patent: June 11, 2019Assignee: SANOFIInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20170321241Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.Type: ApplicationFiled: October 29, 2015Publication date: November 9, 2017Inventors: Claus Lattemann, Thomas Stillger, Bernd Janocha, Hans-Falk Rasser, Sebastian Rissom, Simone Anderko, Rita Bernhardt, Frank Hannemann
-
Publication number: 20170029477Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.Type: ApplicationFiled: July 6, 2016Publication date: February 2, 2017Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20080318942Abstract: The invention relates to new fredericamycin derivatives, to pharmaceutical drugs containing them or their salts, and to the use of the fredericamycin derivatives for the treatment of diseases, especially tumor diseases.Type: ApplicationFiled: September 1, 2006Publication date: December 25, 2008Applicants: BIOAGENCY AG, DISCOVERY PARTNERS INTERNATIONAL GMBHInventors: Werner Simon, Rajendra-Prasad Maskey, Hans-Falk Rasser, Bernd Sontag, Peter Eckard, Iris- Grun-Wollny, Friedrich Hansske, Bjorn Friedrich Lindemann